Beck Capital Management LLC Has $3.89 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Beck Capital Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,324 shares of the company’s stock after buying an additional 193 shares during the quarter. Eli Lilly and Company comprises about 1.7% of Beck Capital Management LLC’s holdings, making the stock its 12th largest position. Beck Capital Management LLC’s holdings in Eli Lilly and Company were worth $3,889,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of LLY. Wellington Management Group LLP grew its holdings in Eli Lilly and Company by 1.6% in the first quarter. Wellington Management Group LLP now owns 20,324,267 shares of the company’s stock worth $6,979,760,000 after purchasing an additional 314,349 shares during the period. Morgan Stanley grew its holdings in Eli Lilly and Company by 44.1% in the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after purchasing an additional 3,691,436 shares during the period. Jennison Associates LLC grew its holdings in Eli Lilly and Company by 3.6% in the fourth quarter. Jennison Associates LLC now owns 10,429,081 shares of the company’s stock worth $3,815,375,000 after purchasing an additional 364,339 shares during the period. Norges Bank acquired a new stake in Eli Lilly and Company in the fourth quarter worth $3,416,206,000. Finally, Moneta Group Investment Advisors LLC grew its holdings in Eli Lilly and Company by 102,752.2% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after purchasing an additional 5,440,731 shares during the period. 81.38% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 2.3 %

Shares of Eli Lilly and Company stock traded up $13.23 during trading on Friday, reaching $586.46. The company’s stock had a trading volume of 4,311,028 shares, compared to its average volume of 2,307,741. Eli Lilly and Company has a 52-week low of $296.32 and a 52-week high of $587.55. The company has a market cap of $556.72 billion, a price-to-earnings ratio of 81.57, a PEG ratio of 2.36 and a beta of 0.32. The firm’s 50-day moving average is $499.40 and its two-hundred day moving average is $428.93. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. The company had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $7.58 billion. During the same quarter in the prior year, the company earned $1.25 EPS. The firm’s revenue was up 28.1% on a year-over-year basis. On average, sell-side analysts anticipate that Eli Lilly and Company will post 9.83 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company’s dividend payout ratio is currently 62.87%.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 27,353 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $454.15, for a total transaction of $12,422,364.95. Following the completion of the sale, the insider now directly owns 101,446,457 shares in the company, valued at approximately $46,071,908,446.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, major shareholder Lilly Endowment Inc sold 27,353 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $454.15, for a total transaction of $12,422,364.95. Following the completion of the sale, the insider now directly owns 101,446,457 shares in the company, valued at approximately $46,071,908,446.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the transaction, the chief accounting officer now owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The disclosure for this sale can be found here. Insiders sold 1,038,161 shares of company stock worth $21,108,177,335 in the last three months. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LLY. StockNews.com began coverage on shares of Eli Lilly and Company in a report on Thursday, August 17th. They issued a “buy” rating for the company. Credit Suisse Group raised their price target on shares of Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $630.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, September 5th. HSBC began coverage on shares of Eli Lilly and Company in a report on Friday, July 14th. They set a “buy” rating and a $560.00 price objective for the company. Finally, Citigroup lifted their price objective on shares of Eli Lilly and Company from $360.00 to $525.00 and gave the company a “buy” rating in a report on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.